Caxton Associates LP Invests $682,000 in BioNTech SE (NASDAQ:BNTX)

Caxton Associates LP purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 8,485 shares of the company’s stock, valued at approximately $682,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Point72 Asset Management L.P. boosted its stake in shares of BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares during the last quarter. Marshall Wace LLP purchased a new stake in BioNTech in the 2nd quarter worth $2,892,000. Discovery Capital Management LLC CT purchased a new stake in shares of BioNTech in the second quarter worth about $2,467,000. Virtu Financial LLC bought a new position in shares of BioNTech during the 2nd quarter valued at approximately $1,586,000. Finally, DekaBank Deutsche Girozentrale lifted its position in BioNTech by 3.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 427,597 shares of the company’s stock valued at $34,533,000 after purchasing an additional 15,700 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BNTX shares. Deutsche Bank Aktiengesellschaft raised their price objective on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $91.00 to $125.00 in a research note on Monday, September 16th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and set a $113.00 price objective on shares of BioNTech in a report on Monday, September 16th. Finally, UBS Group upped their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $127.15.

BioNTech Trading Up 1.6 %

Shares of NASDAQ BNTX opened at $117.64 on Friday. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The business has a fifty day moving average price of $93.23 and a 200 day moving average price of $91.33. The stock has a market capitalization of $27.97 billion, a P/E ratio of 235.28 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the previous year, the company posted ($0.86) earnings per share. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. Equities research analysts expect that BioNTech SE will post -2.87 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.